$2.89 Billion is the total value of Boxer Capital, LLC's 75 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 130.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BGNE | Buy | BEIGENE LTDsponsored adr | $319,148,000 | +83.1% | 1,114,188 | +20.5% | 11.03% | +43.9% |
| RVMD | Buy | REVOLUTION MEDICINES INC | $115,162,000 | +23.3% | 3,309,264 | +11.8% | 3.98% | -3.1% |
| ITOS | New | ITEOS THERAPEUTICS INC | $107,192,000 | – | 4,345,016 | +100.0% | 3.70% | – |
| PMVP | New | PMV PHARMACEUTICALS INC | $80,522,000 | – | 2,268,236 | +100.0% | 2.78% | – |
| ODT | Buy | ODONATE THERAPEUTICS INC | $69,931,000 | -50.9% | 5,207,086 | +54.8% | 2.42% | -61.4% |
| RLAY | New | RELAY THERAPEUTICS INC | $53,321,000 | – | 1,251,959 | +100.0% | 1.84% | – |
| ICPT | Buy | INTERCEPT PHARMACEUTICALS IN | $48,757,000 | +707.6% | 1,176,000 | +833.3% | 1.68% | +535.8% |
| NRIX | New | NURIX THERAPEUTICS INC | $47,282,000 | – | 1,354,392 | +100.0% | 1.63% | – |
| KURA | Buy | KURA ONCOLOGY INC | $32,181,000 | +133.7% | 1,050,289 | +24.3% | 1.11% | +83.8% |
| New | MARINUS PHARMACEUTICALS INC | $30,840,000 | – | 2,400,000 | +100.0% | 1.07% | – | |
| BCEL | Buy | ATRECA INC | $30,767,000 | -16.6% | 2,202,333 | +27.0% | 1.06% | -34.5% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $28,960,000 | +314.9% | 4,000,000 | +100.0% | 1.00% | +226.1% |
| AKRO | Buy | AKERO THERAPEUTICS INC | $25,602,000 | +146.7% | 831,495 | +99.6% | 0.88% | +94.1% |
| PAND | New | PANDION THERAPEUTICS INC | $24,152,000 | – | 2,107,513 | +100.0% | 0.84% | – |
| RACA | New | THERAPEUTICS ACQUISITION COR | $21,570,000 | – | 1,500,000 | +100.0% | 0.74% | – |
| NLTX | Buy | NEOLEUKIN THERAPEUTICS INC | $18,013,000 | +7.5% | 1,501,058 | +48.7% | 0.62% | -15.6% |
| KOD | Buy | KODIAK SCIENCES INC | $16,291,000 | +66.2% | 275,138 | +51.9% | 0.56% | +30.6% |
| LABD | New | DIREXION SHS ETF TRdaily s&p biotec | $14,920,000 | – | 250,000 | +100.0% | 0.52% | – |
| SPPI | New | SPECTRUM PHARMACEUTICALS INC | $13,600,000 | – | 3,333,333 | +100.0% | 0.47% | – |
| MIST | Buy | MILESTONE PHARMACEUTICALS IN | $13,009,000 | +212.3% | 1,777,194 | +61.2% | 0.45% | +145.9% |
| DBVT | Buy | DBV TECHNOLOGIES S Asponsored adr | $13,035,000 | -57.8% | 7,534,598 | +7.1% | 0.45% | -66.9% |
| PSTX | New | POSEIDA THERAPEUTICS INC | $11,097,000 | – | 1,251,055 | +100.0% | 0.38% | – |
| PANA | New | PANACEA ACQUISITION CORPcl a | $8,958,000 | – | 800,000 | +100.0% | 0.31% | – |
| FSDC | New | FS DEV CORP | $7,839,000 | – | 700,000 | +100.0% | 0.27% | – |
| ARVN | New | ARVINAS INC | $7,083,000 | – | 300,000 | +100.0% | 0.24% | – |
| BLU | Buy | BELLUS HEALTH INC NEW | $6,753,000 | -63.0% | 2,975,000 | +67.6% | 0.23% | -71.0% |
| ARYA | New | ARYA SCIENCES ACQUISITION CO | $6,270,000 | – | 600,000 | +100.0% | 0.22% | – |
| HSAQ | New | HEALTH SCIENCES ACQ CORP 2 | $4,400,000 | – | 400,000 | +100.0% | 0.15% | – |
| TARA | New | PROTARA THERAPEUTICS INC | $3,521,000 | – | 209,227 | +100.0% | 0.12% | – |
| GNCA | New | GENOCEA BIOSCIENCES INC | $2,598,000 | – | 1,134,453 | +100.0% | 0.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-11-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.